Moberg Pharma receives favorable outcome from NAD - main competitor to discontinue current marketing
(WorldNews Sweden)

In the spring of 2017, Moberg Pharma filed a challenge to NAD on claims made by Kramer Laboratories, Inc. as for the Original Fungi-Nail Toe & Foot Brand (`Fungi-Nail Toe & Foot`) and Fungi-Nail Nailner. The challenge mainly concerned product packaging, television and print advertising for `Fungi-Nail Toe & Foot`; claiming to treat toenail fungus rather than athlete`s foot which is the approved indication for the product. A more detailed description of NAD`s rationale and conclusion on the challenge is available in a press release from ASRC, please see...